Pancreatic fistula medical therapy

Jump to navigation Jump to search

Pancreatic fistula Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pancreatic fistula from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

ERCP

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pancreatic fistula medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pancreatic fistula medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pancreatic fistula medical therapy

CDC on Pancreatic fistula medical therapy

Pancreatic fistula medical therapy in the news

Blogs on Pancreatic fistula medical therapy

Directions to Hospitals Treating Pancreatic fistula

Risk calculators and risk factors for Pancreatic fistula medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Treatment of pancreatic fistula includes early recognition of the problem which is the key to careful management in order to prevent the consequent complications. Medical therapy is tailored towards the suppression of pancreatic enzymes by restricting the patient's oral intake of food in conjunction with the use of long-acting somatostatin analogues such as octreotide. Correction of the fluid and electrolyte abnormalities. The patient's nutrition is maintained by total parenteral nutrition. This treatment is continued for 2-3 weeks, and the patient is observed for improvement.

Medical Therapy

Treatment of pancreatic fistula includes early recognition of the problem which is the key to careful management in order to prevent the consequent complications.

References

  1. Takeo C, Myojo S (2000). "Marked effect of octreotide acetate in a case of pancreatic pleural effusion". Curr Med Res Opin. 16 (3): 171–7. PMID 11191006.
  2. "StatPearls". 2021. PMID 32809706 Check |pmid= value (help).
  3. Nahm CB, Connor SJ, Samra JS, Mittal A (2018). "Postoperative pancreatic fistula: a review of traditional and emerging concepts". Clin Exp Gastroenterol. 11: 105–118. doi:10.2147/CEG.S120217. PMC 5858541. PMID 29588609.

Template:WH Template:WS